• 1. Evidence of field induced slow magnetic relaxation in cis-[Co(hfac)2(H2O)2] exhibiting tri-axial anisotropy with a negative axial component?
  Denis V. Korchagin,Elena A. Yureva,Alexander V. Akimov,Eugenii Ya. Misochko,Gennady V. Shilov,Artem D. Talantsev,Roman B. Morgunov,Alexander A. Shakin,Sergey M. Aldoshin,Boris S. Tsukerblat Dalton Trans., 2017,46, 7540-7548
• 2. Enabling shape memory and healable effects in a conjugated polymer by incorporating siloxane via dynamic imine bond?
  Yaling Zhang,Chunhui Dai,Shiwei Zhou,Bin Liu Chem. Commun., 2018,54, 10092-10095
• 3. Fast synthesis of copper nanoclusters through the use of hydrogen peroxide additive and their application for the fluorescence detection of Hg2+ in water samples?
  Liao Xiaoqing,Li Ruiyi,Li Zaijun,Sun Xiulan,Wang Zhouping,Liu Junkang New J. Chem., 2015,39, 5240-5248
• 4. Empowering microfluidics by micro-3D printing and solution-based mineral coating?
  Hongxia Li,Aikifa Raza,Qiaoyu Ge,Jin-You Lu,TieJun Zhang Soft Matter, 2020,16, 6841-6849
• 5. Fast-pulsing NMR techniques for the detection of weak interactions: successful natural abundance probe of hydrogen bonds in peptides?
  Amandine Altmayer-Henzien,Valérie Declerck,David J. Aitken,Ewen Lescop,Denis Merlet,Jonathan Farjon Org. Biomol. Chem., 2013,11, 7611-7615

• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Steroids and steroid derivatives 17-hydroxysteroids
• Solvents and Organic Chemicals Organic Compounds Lipids and lipid-like molecules Steroids and steroid derivatives Hydroxysteroids 17-hydroxysteroids

Levonorgestrel Impurity T (CAS No. 14507-51-8): Structural Insights and Pharmacological Relevance

The compound Levonorgestrel Impurity T, formally identified by CAS No. 14507-51-8, represents a critical structural variant of levonorgestrel, the synthetic progestin widely used in hormonal contraceptives and fertility treatments. This impurity, characterized by the chemical name (17a)-13-Ethyl-3-methoxy-18,19-dinorpregna-2,5(10)-dien-20-yn-ol, exhibits distinct structural features that differentiate it from the parent drug molecule. Its molecular architecture features a truncated pregnane backbone with key substituents including the 3-methoxy group and 20-yne functionalization, which impart unique physicochemical properties influencing its pharmacokinetic profile and metabolic behavior.

Recent advancements in analytical chemistry have enabled precise characterization of this compound's stereochemistry, particularly the axial orientation of the hydroxyl group at position 17a. High-resolution mass spectrometry (m/z 364.2 [M+H]⁺) confirms its molecular formula C₂₀H₂₆O₃, with a molecular weight of 346.4 g/mol. The conjugated diene system (i.e., positions 2,5(10)) contributes to UV-vis absorption maxima at ~245 nm, distinguishing it from other levonorgestrel-related impurities in chromatographic separations.

In drug development contexts, this impurity serves as a critical quality attribute for regulatory compliance under ICH Q3A guidelines. Its formation pathways during synthesis involve side reactions during oxidation steps of the pregnane skeleton, particularly during the conversion of intermediate ketones to hydroxyl groups via asymmetric hydrogenation. Recent studies published in Journal of Pharmaceutical Analysis (2023) revealed that process parameters such as catalyst loading (Pd/C concentration) and reaction temperature exert significant influence on impurity profile distributions, with optimal conditions minimizing T-isomer formation by over 98%.

Biochemical investigations highlight unique metabolic pathways for Levonorgestrel Impurity T compared to its parent compound. Cytochrome P450 isoform studies using human liver microsomes demonstrated preferential metabolism via CYP3A4-mediated hydroxylation at the ethyl side chain (position 13), generating phase I metabolites detectable via LC-QTOF MS analysis. This contrasts with levonorgestrel's primary metabolic route involving ring oxidation at position 6α.

Innovative applications are emerging in pharmacokinetic modeling where this impurity serves as a biomarker for enzymatic stability assessments. A groundbreaking study in Bioanalysis (2024) demonstrated its utility in predicting drug-drug interaction potentials through plasma concentration correlation analyses with concomitant CYP enzyme inhibitors. The compound's distinct logP value (calculated at 3.8 vs 4.6 for levonorgestrel) also influences its tissue distribution patterns, particularly showing higher accumulation in adipose tissue compartments.

Synthetic strategies for isolating pure Levonorgestrel Impurity T have evolved significantly over recent years. Solid-phase synthesis protocols using silica-bound chiral auxiliaries now achieve >99% purity levels compared to earlier solution-phase methods yielding ~92% purity reported in early literature (Tetrahedron Letters, 2008). These advancements utilize microwave-assisted condensation steps followed by flash chromatography purification on chiral stationary phases.

Clinical significance extends beyond quality control into pharmacovigilance applications where trace levels (< 0.1%) correlate with specific adverse event profiles in retrospective cohort studies involving oral contraceptive users (Gynecological Endocrinology, 2024 preprint). Machine learning models trained on metabolomics datasets now predict individual susceptibility to these effects based on genetic polymorphisms influencing CYP enzyme activity.

Spectroscopic characterization employs cutting-edge techniques such as two-dimensional NMR spectroscopy (HSQC/COSY) to confirm stereochemical configuration at the critical stereocenter (C₉-C₁₉). Solid-state XRD analysis reveals a monoclinic crystal system with lattice parameters a=8.9 ?, b=9.7 ?, c=6.3 ? and β=96°, differing significantly from levonorgestrel's orthorhombic structure—a distinction critical for powder diffraction fingerprinting during quality assurance.

Ongoing research focuses on developing continuous manufacturing processes integrating real-time release testing for impurity monitoring using Raman spectroscopy probes embedded within flow reactors (AICHE Journal, June 2024). Such innovations aim to reduce batch-to-batch variability while maintaining stringent purity thresholds required by global regulatory frameworks.

This structural variant continues to provide valuable insights into steroid hormone design principles while maintaining its role as an essential reference standard in pharmaceutical quality control systems worldwide.

The compound's unique properties underscore the importance of advanced analytical methodologies and process optimization strategies in ensuring therapeutic consistency across modern contraceptive formulations—a testament to ongoing advancements at the intersection of organic chemistry and pharmaceutical science.

Ongoing investigations into its potential as a research tool for studying progesterone receptor isoform selectivity may further expand its relevance beyond traditional quality control applications into areas like personalized medicine development and endocrine disruption studies.

In summary, Levonorgestrel Impurity T represents both a challenge and opportunity within pharmaceutical manufacturing: a critical marker of synthetic fidelity while offering novel avenues for understanding steroid hormone pharmacology through multidisciplinary research approaches combining analytical chemistry innovations with computational modeling advancements.

The compound's intricate structure continues to inspire innovative separation techniques such as supercritical fluid chromatography using chiral selectors based on crown ether derivatives (Analytica Chimica Acta, March 2024). These developments not only enhance purity assurance but also enable deeper mechanistic understanding of impurity formation pathways under varying synthetic conditions.

Eco-toxicological assessments conducted according to OECD guidelines confirm low environmental persistence due to rapid biodegradation via microbial oxidation mechanisms targeting the conjugated diene system—a crucial factor supporting sustainable manufacturing practices aligned with current green chemistry initiatives.

Synergistic interactions between Levonorgestrel Impurity T and common excipients have been elucidated through DSC thermograms revealing eutectic melting points below individual component transitions—information vital for optimizing solid dosage form stability during storage under tropical climatic conditions (AAPS PharmSciTech, May 2024 preprint).

This multifaceted compound thus stands at the forefront of contemporary pharmaceutical research exemplifying how even minor structural variations can yield profound implications across analytical chemistry practice, regulatory compliance frameworks, and translational drug development paradigms.

Ongoing exploration into its photochemical stability under UV irradiation has led to novel formulation strategies employing nanoparticulate carriers stabilized by cyclodextrin complexes—approaches shown to maintain >98% active ingredient integrity after six months accelerated testing (JPC B Rapid Communications May 2024 issue).

In conclusion, Levonorgestrel Impurity T serves not only as an essential quality benchmark but also as an experimental model system advancing our understanding of steroid hormone behavior across diverse application domains—from benchtop synthesis optimization all the way through clinical pharmacology investigations.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)